A5073205245- Heart Failure Treatment and Management
- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
- Lipoproteins and Cardiovascular Health
- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Mechanical Circulatory Support Devices
- Venous Thromboembolism Diagnosis and Management
- Healthcare Systems and Practices
- Cardiac Health and Mental Health
- Cardiac Imaging and Diagnostics
- Health, Medicine and Society
- Cardiac pacing and defibrillation studies
- Blood Pressure and Hypertension Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac, Anesthesia and Surgical Outcomes
- Patient Satisfaction in Healthcare
- Pharmaceutical Economics and Policy
- Peptidase Inhibition and Analysis
- Patient-Provider Communication in Healthcare
- Hormonal Regulation and Hypertension
University of Alberta
2016-2025
University of British Columbia
2005-2024
Centre for Advancing Health Outcomes
2024
University of Ottawa
2023
Alberta Hospital Edmonton
2012-2023
Canadian VIGOUR Centre
2019-2021
Barry University
2016-2020
Regina General Hospital
2018-2020
Native Mental Health Association of Canada
2020
University of Saskatchewan
2011-2020
Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents heart failure. We hypothesized that angiotensin-converting could prevent trastuzumab-related cardiotoxicity. Patients Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early were randomly...
<h3>Importance</h3> Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which reduced major adverse events (MACE) vs but increased bleeding and dyspnea. <h3>Objective</h3> To compare the risk of MACE ACS treated percutaneous intervention (PCI), to dyspnea, evaluate association between P2Y<sub>12</sub>inhibitor adherence MACE. <h3>Design, Setting, Participants</h3> Population-based cohort study...
Background: Medical inpatients are at risk for suboptimal health outcomes from adverse drug events and under-use of evidence-based therapies. We sought to determine whether collaborative care including a team-based clinical pharmacist improves the quality prescribed therapy reduces hospital readmission. Methods: Multicenter, quasi-randomized, controlled trial. Consecutive patients admitted 2 internal family medicine teams in 3 teaching hospitals between January 30, 2006 February 2, 2007 were...
Abstract Background MANTICORE 101 - Breast (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) is a randomized trial determine if conventional heart failure pharmacotherapy (angiotensin converting enzyme inhibitor or beta-blocker) can prevent trastuzumab-mediated left ventricular remodeling, measured with cardiac MRI, among patients HER2+ early breast cancer. Methods/Design One hundred and fifty-nine histologically confirmed cancer will be enrolled parallel 3-arm,...
An improved understanding of the pathophysiology trastuzumab-mediated cardiotoxicity is required to improve outcomes patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We aimed characterize cardiac and cardiometabolic phenotype toxicity potential interactions pharmacotherapy.This study was an analysis serial magnetic resonance imaging (MRI) circulating biomarker data acquired from HER2-positive early-stage cancer participating in a randomized-controlled...
Abstract Aims Post-acute coronary syndrome (ACS) P2Y12 inhibitor non-adherence is common and associated with greater risk of major adverse cardiovascular events (MACEs). Non-adherence can follow different trajectories from an inability to initiate, implement, or continue therapy for the intended duration. We aimed evaluate adherence among ACS patients treated percutaneous intervention (PCI), their frequency, association MACE. Methods results conducted a cohort study adults discharged alive...
Introduction Venetoclax is a BCL-2 inhibitor, used for both treatment-naive, and relapsed/refractory chronic lymphocytic leukemia (CLL). To mitigate the risk of tumor lysis syndrome (TLS), 5-week dose ramp-up strategy with frequent assessment required. Pharmacists are medication experts skilled in managing adverse effects. They ideally positioned to manage patients during can reduce hematologist visits. We sought describe impact pharmacist-led venetoclax clinic implemented at our...
In 2014, ibrutinib, a covalent Bruton’s tyrosine kinase inhibitor (BTKi), became available as treatment for chronic lymphocytic leukemia (CLL) in Canada. It was welcomed with enthusiasm given its oral administration, lower rate of neutropenia and infections, efficacy heavily pretreated high-risk del17p subtypes, at time when only chemotherapy monoclonal antibodies were available. Soon adverse events (AE) due to off-target effects emerged; particularly concerning cardiac arrhythmias,...
OBJECTIVE: To report the case of a patient who underwent orthotopic heart transplant (OHT) and demonstrated supratherapeutic response to ezetimibe when administered with cyclosporine. CASE SUMMARY: Ezetimibe 10 mg/day was added lipid-lowering regimen (atorvastatin 40 mg/day) 64-year-old male after OHT achieve target low-density lipoprotein cholesterol (LDL-C) level ≤97 mg/dL, as recommended by national guidelines. After 2 months ezetimibe, patient's LDL-C had decreased 60% 51 mg/dL....
BACKGROUND: The development of tools to support shared decision-making should be informed by patients’ decisional needs and treatment preferences, which are largely unknown for heart failure (HF) with reduced ejection fraction (HFrEF) pharmacotherapy decisions. We aimed identify when considering HFrEF medication options. METHODS: This was a qualitative study using semi-structured interviews. recruited patients from 2 Canadian ambulatory HF clinics clinicians guideline panels, clinics,...
A patient with metastatic renal cell carcinoma on axitinib and pembrolizumab had elevated high-sensitivity cardiac troponin T normal I unremarkable investigations. noncardiac cause (myositis) was the likely for elevation. Cardiac may be a more appropriate marker to support myocarditis diagnosis concurrent myositis.
Results of a survey to determine the frequency prescribing by Canadian hospital pharmacists with independent authority are reported.A Web-based questionnaire was used collect data on activities designated group hospital-affiliated in province Alberta who had been granted "additional authorization" (APA) through peer-review process and were providing clinical pharmacy services inpatient and/or outpatient settings at time (January-March 2014). Descriptive statistics logistic regression...